CYB003 explained

CYB003, or CYB-003, also known as deuterated psilocybin analogue, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders.^{[1] [2] [3] [4] [5] [6]} It is taken by mouth.

It is a tryptamine derivative and is a deuterated analogue of psilocybin and psilocin. The pharmacodynamic profile of CYB003, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin. As with psilocin, CYB003 is a potent agonist of the serotonin 5-HT_2A receptor and produces psychedelic-like effects in animals. However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration.

As of October 2024, CYB003 is in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders. Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025. The drug is under development by Cybin. The chemical structure of CYB003 has not yet been disclosed.^[7] However, Cybin patented deuterated tryptamines including the dideuterated psilocin analogue PI-α,α-d₂ (psilocin dideuterated at the α carbon) in 2023.^[8] Other related drugs include the deuterated tryptamine CYB004 and the deuterated phenethylamines CYB005 and CYB210010.^[9]

See also

• List of investigational hallucinogens and entactogens
• List of investigational antidepressants

External links

• CYB003 – Cybin

Notes and References

1. Web site: CYB 003 . AdisInsight . 4 October 2024 . 23 October 2024.
2. Web site: Delving into the Latest Updates on CYB-003 with Synapse . Synapse . 12 October 2024 . 23 October 2024.
3. Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B . Key Characteristics and Development of Psychoceuticals: A Review . Int J Mol Sci . 23 . 24 . December 2022 . 15777 . 36555419 . 9779201 . 10.3390/ijms232415777 . free .
4. Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST . Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders . Drug Discov Today . 28 . 12 . 103818 . December 2023 . 37925136 . 10.1016/j.drudis.2023.103818 .
5. Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G . ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder . Neuropsychopharmacology . 47 . Suppl 1 . 220–370 (271) . December 2022 . 36456694 . 9714399 . 10.1038/s41386-022-01485-0 .
6. Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, Avery K, Pathare P, Hartsel J, Nivorozhkin A, Varty G, Palfreyman M . ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder . Neuropsychopharmacology . 47 . Suppl 1 . 220–370 (271–272) . December 2022 . 36456694 . 9714399 . 10.1038/s41386-022-01485-0 .
7. Di Martino RM, Maxwell BD, Pirali T . Deuterium in drug discovery: progress, opportunities and challenges . Nat Rev Drug Discov . 22 . 7 . 562–584 . July 2023 . 37277503 . 10241557 . 10.1038/s41573-023-00703-8 .
8. Web site: Deuterated tryptamine derivatives and methods of use . Google Patents . 17 July 2023 . 23 October 2024 . Binding affinity (Ki) and functional potency (EC50) values of PI and PI-α-d2 are summarized in Table 1. Deuteration was found to have little effect on the affinity and function at key receptor targets. [...] TABLE 1: PI and PI-α,α-d2 Affinities and Functions at Target Serotonin Receptors [...].
9. Peplow M . Next-generation psychedelics: should new agents skip the trip? . Nat Biotechnol . 42 . 6 . 827–830 . June 2024 . 38831049 . 10.1038/s41587-024-02285-1 .